Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

difelikefalin (Korsuva)

Therapeutic Area: Chronic kidney disease
Draft recommendations posted for stakeholder feedback:  March 16, 2023
End of feedback period: March 31, 2023
Draft Recommendation

Submit Feedback

 

deucravacitinib (Sotyktu)

Therapeutic Area: Psoriasis, moderate to severe plaque
Draft recommendations posted for stakeholder feedback:  March 16, 2023
End of feedback period: March 31, 2023
Draft Recommendation

Submit Feedback

 

mavacamten (Camzyos)

Therapeutic Area: Obstructive hypertrophic cardiomyopathy
Draft recommendations posted for stakeholder feedback:  March 16, 2023
End of feedback period: March 31, 2023
Draft Recommendation

Submit Feedback

Open Calls for Patient and Clinician Input

 

Emergency Department Overcrowding in Canada: An Update

End of feedback period: September, 2023

Statements of Interest

Livmarli ( maralixibat )
Therapeutic Area
Therapeutic Area: Alagille syndrome
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Vyvgart ( efgartigimod alfa )
Therapeutic Area
Therapeutic Area: Generalized myasthenia gravis (gMG).
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Rinvoq ( upadacitinib )
Therapeutic Area
Therapeutic Area: Crohns disease
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
TBC ( evinacumab )
Therapeutic Area
Therapeutic Area: Homozygous familial hypercholesterolemia (HoFH)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Lynparza ( olaparib )
Therapeutic Area
Therapeutic Area: Metastatic castration-resistant prostate cancer (mCRPC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Sogroya ( somapacitan )
Therapeutic Area
Therapeutic Area: Growth Hormone Deficiency (GHD)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
TBC ( calaspargase pegol )
Therapeutic Area
Therapeutic Area: Acute lymphoblastic leukemia (ALL)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Imbruvica ( ibrutinib )
Therapeutic Area
Therapeutic Area: Chronic lymphocytic leukemia (CLL)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Adcetris ( brentuximab vedotin )
Therapeutic Area
Therapeutic Area: Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
N/A ( bevacizumab and lomustine )
Therapeutic Area
Therapeutic Area: Recurrent glioblastoma multiform
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: